CD4 and melanoma: revealed coordinated anti‐tumor activity between T cells and neutrophils during immunotherapy, where tumor‐specific CD4+ T cells initiate responses against melanoma antigens while neutrophils eliminate antigen‐loss variants.[190] Consistently, Cui et al.